Clinuvel Pharmaceuticals (CUV)

Download button icon Download

Clinuvel Pharmaceuticals (CUV): Signals

No data currently available.

data-ad-format="auto">

Explore Compare Share

TECHNICAL ANALYSIS SUMMARY

Clinuvel Pharmaceuticals (CUV.AX)


Indicator:

SIMPLE MOVING AVERAGE


Last Signal:

BULLISH


Trading: BUY @ $19.19
Signal Strength: STRONG
Recommendation:

Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading entry. This indicator has the ability to highlight trends across numerous timeframes. This indicator has the ability to smooth historical results to illustrate trend initiation and status. Although this is a simple trend following indicator & can provide good results when coupled with the right indicator. Note, this indicator does not work well in ranging markets producing unwanted whipsaws and false signals.


Clinuvel Pharmaceuticals (ASX:CUV) currently has a confirmed uptrend. This means the SMA 15 day average has exceeded the closing price confirming the short term trend following indicator. Currently, the return on SMA15 is -8.5%.



A simple moving average is formed by computing the average price of a security over a specific number of periods. Most moving averages are based on closing prices.

Calculation: Simple Moving Average:
1) SMA: n period sum / n;


PROFILE: Clinuvel Pharmaceuticals (CUV.AX)


Stock Exchange: ASX
Company: Clinuvel Pharmaceuticals
Ticker Codes: | CUV.AX | ASX:CUV |

About Clinuvel Pharmaceuticals (ASX:CUV):

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing drugs for the treatment of a range of severe skin disorders. Its lead drug compound is SCENESSE, a medicinal photoprotective and repigmentation drug that has completed Phase II and III trials in the United States and Europe, which is used for the prevention of phototoxicity in adults with erythropoietic protoporphyria. The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue that acts as a potent skin protectant; and VLRX001, an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity. It has operations in Europe, the United States, and Singapore. The company is headquartered in Melbourne, Australia.

Top 10:

Simple Moving Average

Download button icon Download
Company Close Change (%) Volume Value Signal
ELD ELD 8.87 19.7 1,640,097 19.7 BULLISH
HSO Healthscope 2.38 14.4 40,437,560 13.2 BULLISH
FLN Freelancer 0.88 12.9 1,312,856 29 BULLISH
MNS Milnes Holdings 0.37 12.3 2,277,569 21.7 BULLISH
LYC Lynas Corporation 2.4 9.6 12,451,685 20.6 BULLISH
LYL Lycopodium 5 8.7 110,499 10.5 BULLISH
DNA Donaco International 0.19 8.6 223,280 13.8 BULLISH
CVW Clearview Wealth 0.96 7.9 88,268 12.1 BULLISH
VTG Vita 1.14 6.5 609,580 13.2 BULLISH
OHE Orion Health 1.1 5.8 7,450 16.6 BULLISH
back to top